Targeted therapies in advanced GC with Epstein-Barr virus positive patients, can be applied to the PIK3CA/Akt pathway, JAK2 and PD-1/PD-L1, and PD-L2 pathway [22]. Here, AKT1 is linked to gastric cancer.